Patients On Oral Anticancer Drugs And Coordinated Pathway: Chimoral, Feedback From Care Providers

Introduction > Oral anticancer drugs have raised the question of how to follow-up these patients and how to coordinate this follow-up. The CHIMORAL study evaluated the involvement of primary core providers and a coordination by territorial health networks. Training/information tools were provided, as well os weekly nursing follow-up of home.Methods > The operational feasibility of this model was assessed through a qualitative/quantitative analysis of territorial health network intervention and feedback from primary core providers.Results > One hundred and fifty four patients received coordinated care, with nursing follow-up for 89% of them (average 6.3 weeks). One in three nurses, one in five pharmacists and one in ten doctors used the tools provided, 41% of which were used for training and 16% for the management of on adverse event. The main reasons for using the networks concerned adverse effects (34%) and came mainly from nurses (45%) and patients and their relatives (47%). Patients felt safe, with more responsive management.Discussion > This intervention has strengthened the networks' links with primary care providers. The use of the community-based care system for adverse events was more frequent, with improved detection and patient awareness, with no observed impact on compliance. A proposed evolution is to maintain an in-home assessment for all patients and to define a frequency and duration of follow-up according to the patient's profile.